New Medication Available Soon
The Food and Drug Administration (FDA) approved Eli Lilly's new weight-loss pill, Foundayo, on April 1, 2026. This once-daily oral medication, known scientifically as orforglipron, will begin shipping on April 3. Foundayo is the second oral GLP-1 medication to enter the market, following the approval of Novo Nordisk's Wegovy pill in December 2025.
Cost and Accessibility
Foundayo will be available in six doses, with the lowest dose priced at approximately $149 per month for those paying out of pocket. Higher doses may cost up to $349 monthly. The company anticipates that patients with insurance might access the drug for as low as $25 per month using a Lilly discount card. Medicare coverage could start this summer under a Trump administration plan, potentially reducing copayments to as low as $50 monthly for eligible patients.
Effectiveness and Clinical Results
In clinical trials involving over 3,000 adults with obesity, participants taking the highest dose of Foundayo experienced an average weight loss of 11.2% to 12.4% after 72 weeks, depending on the study. While this result is comparable to Wegovy, it is less effective than injectable options like Lilly's Zepbound, which has shown an average weight loss of 21%, according to PBS NewsHour. Dr. Jody Dushay, an endocrinologist at Harvard Medical School, noted that many patients transitioning from injections to pills have reported lower weight loss outcomes.
User Experiences and Side Effects
Maggie Linton, a 77-year-old participant in the Foundayo clinical trial, reported losing nearly 60 pounds and experiencing improvements in her blood pressure and cholesterol levels. Although she gained back some weight after the trial, she expressed interest in resuming the medication to reach her weight goals. Gastrointestinal side effects including nausea, constipation, and diarrhea led 5% to 10% of Foundayo participants to discontinue treatment, compared with nearly 3% in the placebo group.
Market Competition and Future Developments
The approval of Foundayo intensifies competition in the growing GLP-1 market, which includes various treatments offering improved weight loss and lower prices. Eli Lilly's CEO, David Ricks, emphasized the importance of making weight loss medications more accessible, stating that fewer than 1 in 10 people who could benefit from GLP-1 treatments are currently using them, according to The Guardian US. The company is also developing another GLP-1 drug, retatrutide, which has shown promising weight loss results in trials.
Conclusion: A New Era in Weight Management
Foundayo offers a pill-based alternative to injectable GLP-1 medications, appealing to patients who prefer oral medication or have difficulty with injections. However, its lower weight loss compared to injectables means it may not suit all patients seeking maximum results.
